# Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

> **NCT00146562** · PHASE2 · COMPLETED · sponsor: **Harold J. Burstein, MD, PhD** · enrollment: 135 (actual)

## Conditions studied

- Breast Cancer
- Stage I Breast Cancer
- Stage II Breast Cancer

## Interventions

- **DRUG:** Darbepoetin Alfa
- **DRUG:** Pegfilgrastim
- **DRUG:** Paclitaxel
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00146562
- **Lead sponsor:** Harold J. Burstein, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2023-08-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00146562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00146562, "Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00146562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*